VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
LMNDLemonade, Inc.
$58.86$4.5B
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HomeStocksLMNDFinancials

Lemonade, Inc. (LMND) Financials

9Y historyFree accessUpdated daily

Revenue growth accelerated to 55.0% in 2026Q1, though the company remains unprofitable with a combined ratio of 114.8% indicating continued underwriting strain.

LMND Income Statement

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17
Revenue821.1M737.9M526.5M429.8M256.7M128.4M94.4M67.3M22.5M2.4M
Revenue Growth %46.99%40.15%22.5%67.43%99.92%36.02%40.27%199.11%837.5%-
Medical Costs & Claims430.4M440.7M353.8M339.6M228.3M105.5M74M55.4M19.4M0
Medical Cost Ratio %52.42%59.72%67.2%79.01%88.94%82.17%78.39%82.32%86.22%0%
Gross Profit390.7M297.2M172.7M90.2M28.4M22.9M20.4M11.9M3.1M2.4M
Gross Margin %47.58%40.28%32.8%20.99%11.06%17.83%21.61%17.68%13.78%100%
Gross Profit Growth %-72.09%91.46%217.61%24.02%12.25%71.43%283.87%29.17%-
Operating Expenses524.8M458.1M376.6M320M323.2M256.5M141.2M119.8M55.7M28.7M
OpEx / Revenue %63.91%62.08%71.53%74.45%125.91%199.77%149.58%178.01%247.56%1195.83%
Depreciation & Amortization13.4M15.2M20M20M12.2M3.7M1.7M600K100K28M
Combined Ratio %116.33%121.81%138.73%153.47%214.84%281.93%227.97%260.33%333.78%1195.83%
Operating Income-134.1M-160.9M-203.9M-229.8M-294.8M-233.6M-120.8M-107.9M-52.6M-26.3M
Operating Margin %-16.33%-21.81%-38.73%-53.47%-114.84%-181.93%-127.97%-160.33%-233.78%-1095.83%
Operating Income Growth %-21.09%11.27%22.05%-26.2%-93.38%-11.96%-105.13%-100%-
EBITDA-120.7M-145.7M-183.9M-209.8M-282.6M-229.9M-119.1M-107.3M-52.5M1.7M
EBITDA Margin %-14.7%-19.75%-34.93%-48.81%-110.09%-179.05%-126.17%-159.44%-233.33%70.83%
Interest Expense0000000000
Non-Operating Income0000000000
Pretax Income-134.1M-160.9M-203.9M-229.8M-294.8M-233.6M-120.8M-107.9M-52.6M-28M
Pretax Margin %-16.33%-21.81%-38.73%-53.47%-114.84%-181.93%-127.97%-160.33%-233.78%-1166.67%
Income Tax4.8M4.6M-1.7M7.1M3M7.7M1.5M600K300K100K
Effective Tax Rate %-3.58%-2.86%0.83%-3.09%-1.02%-3.3%-1.24%-0.56%-0.57%-0.36%
Net Income-138.9M-165.5M-202.2M-236.9M-297.8M-241.3M-122.3M-108.5M-52.9M-28.1M
Net Margin %-16.92%-22.43%-38.4%-55.12%-116.01%-187.93%-129.56%-161.22%-235.11%-1170.83%
Net Income Growth %36.08%18.15%14.65%20.45%-23.41%-97.3%-12.72%-105.1%-88.26%-
EPS (Diluted)-1.82-2.30-2.85-3.40-4.59-3.94-2.21-2.49-1.21-2.58
EPS Growth %37.17%19.3%16.18%25.93%-16.5%-78.28%11.24%-105.79%53.1%-
EPS (Basic)--2.30-2.85-3.40-4.59-3.94-2.21-2.49-1.21-2.58
Diluted Shares Outstanding76.31M71.82M71.02M69.66M64.92M61.22M55.32M43.61M43.61M10.89M

Key Metrics

Growth RegimeAccelerating
ProfitabilityNegative
Balance SheetAdequate
Cash FlowBurning
Top Statement Risk

Persistent Underwriting Loss Volatility

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q1)

Aggressive Revenue Expansion Amidst Scale

According to the provided financial data, Lemonade achieved a 55.0% year-over-year revenue growth in 2026Q1, signaling a robust expansion phase that continues to outpace the company's historical growth rates observed in earlier periods like 2024Q3, where growth was reported at a more modest 19.3%.

The acceleration in top-line growth suggests that the company's multi-line strategy is successfully capturing market share, likely driven by the cross-selling of Homeowners and Pet insurance to the existing Renters base. However, investors should monitor whether this rapid scaling is being achieved through sustainable organic acquisition or if it relies heavily on the 'Synthetic Agents' financing program, which may mask the true cost of customer acquisition.

Underwriting Profitability Remains Structurally Strained

Based on reported figures, the combined ratio in 2026Q1 stood at 114.8%, which, while an improvement from the 148.2% peak observed in 2024Q3, indicates that the company continues to operate at an underwriting loss, necessitating reliance on external capital to fund ongoing operational deficits.

The persistent combined ratio above 100% suggests that the company's AI-driven underwriting has yet to achieve the consistent loss-ratio efficiency required for standalone profitability. The volatility in the loss ratio, which fluctuated between 35.7% and 73.7% over the last ten quarters, implies that the model remains highly sensitive to external catastrophe events and inflationary pressures in the auto and property segments.

Capital-Light Model Faces Reinsurance Headwinds

As indicated by the income statement trends, the company's reliance on proportional reinsurance treaties creates a structural ceiling on gross margins, with the 2026Q1 combined ratio of 114.8% highlighting the difficulty of achieving profitability when a significant portion of premiums is ceded to third-party reinsurers.

The reliance on ceding commissions to offset operating expenses warrants further investigation, as any hardening in the reinsurance market could force a compression of margins. If the company cannot demonstrate a path to reducing its reliance on these treaties, the 'capital-light' thesis may be challenged by the reality of high reinsurance costs and limited underwriting control.

Integration Risks and Operational Volatility

Financial statements reveal that the integration of Metromile and the subsequent expansion into the auto insurance market have contributed to significant earnings volatility, with operating income reaching a low of -$65.8M in 2024Q3 before showing signs of stabilization at -$34.6M in the most recent quarter.

The shift into the auto segment appears to have introduced a higher severity risk profile that the company's algorithms are still calibrating. Investors should monitor whether the recent narrowing of operating losses represents a permanent inflection toward efficiency or merely a temporary fluctuation in claim frequency.

LMND — Frequently Asked Questions

Quick answers to the most common questions about buying LMND stock.

What was Lemonade, Inc.'s (LMND) revenue in 2025?

For fiscal year 2025, Lemonade, Inc. (LMND) reported total revenue of $737.9M. This represents a 30645.8% increase compared to $2.4M in 2017.

Is Lemonade, Inc. (LMND) profitable?

Lemonade, Inc. (LMND) reported a net loss of $165.5M for the fiscal year ending 2025.

What is Lemonade, Inc.'s operating profit margin?

Lemonade, Inc. (LMND) reported an operating income of $-160.9M, resulting in an operating profit margin of -21.8%. This margin reflects the operational efficiency of the business before interest and taxes.

What is Lemonade, Inc.'s gross profit and gross margin?

Lemonade, Inc. (LMND) generated $297.2M in gross profit for the year, representing a gross profit margin of 40.3%. This demonstrates the company's core pricing power and production efficiency.